The European initiative IMI 2 will soon launchnew call for proposal, Call 10.
Currently you can sign up for the informative webinars for following topics.
The Association of Innovative Pharmaceutical Industry would like to point out the new opportunity for Czech research teams dealing with those research areas. Oncoming Call 10 offers the perfect opportunity for the research teams by applying their researches and results in joint projects with the pharmaceutical industry and European research leaders.
Call for proposal 10 is focused on hypoglycaemia, Prostate Cancer in conection with Big Data for Better Outcomes, acute and chronic pain, autism spectrum disorders, paediatric clinical trials and more.
Scheduled topics of Call 10 are follows:
Detailed information about Call 10 topics:
Currently you can apply for IMI webinars explaining each topic of 10th Call for proposals.
All webinars on the Call topics will feature a presentation by the EFPIA (European Federation of Pharmaceutical Industries and Associations) topic coordinator and time for questions and answers. The webinars will be an excellent opportunity to learn more about the topics, ask questions to topic coordinators and the IMI Programme Office representatives, and get in touch with potential project partners.
Information and registration for the webinars:
INFORMATIVE SEMINAR IN PRAGUE:
Association of Innovative Pharmaceutical Industry (AIFP) is planning to organise an informative seminar related to the 10th Cal for proposals.
The seminar will explain each topic in more details, clarify the method of applying for the Call, and highlight the experiences from previous participations in projects and even more.
The seminar will be attended by representatives of EFPIA (European Federation of Pharmaceutical Industries and Associations) and the representatives of IMI (Innovative Medicines Initiative).
Expected date of the seminar is the end of January 2017.
We welcome your preliminary statement whether you are interested in this seminar.
If interested, please contact us via e-mail: